Clinical Trial Protocol
Iranian Registry of Clinical Trials

30 May 2026

Study of the Efficacy of Teicoplanin on mortality rate of patients with COVID-19 Infection: A randomized clinical trial

Protocol summary

Study aim
Evaluation of the Effect of Ticoplanin in Patients With Coronavirus Disease

Design
A clinical trial with controlled group، not blinded، randomized

Settings and conduct
This study will be performed in Rasoul Akram Hospital Tehran. 40 patients will be divided into two groups (20 in each group) by simple randomization. Patients in the control group will be prescribed a standard regimen for COVID-19. The intervention group will be prescribed teicoplanin 400 mg IV one time daily for seven days and standard regimen for COVID-19. The routine lab data blood cell count, ESR, CRP, CT scan of lungs, hospitalization period, and mortality rate, clinical improvement and radiology finding will be assessed in both groups.

Participants/Inclusion and exclusion criteria
Inclusion Criteria: Laboratory confirmed COVID-19 with RT-PCR or CT scan; Exclusion criteria: Chronic kidney Disease، Acute kidney injury، Pregnancy or breastfeeding

Intervention groups
Control group: will receive standard regimen for COVID-19. Teicoplanin group: will receive standard regimen for COVID-19 plus teicoplanin 400 mg/daily for 7 days.

Main outcome variables
Clinical symptoms، The change of pneumonia severity on CT scanning، Laboratory and radiologic finding changes

General information

Reason for update

Acronym

IRCT registration information
IRCT registration number: **IRCT20161204031229N3**
Registration date: **2020-04-08, 1399/01/20**
Registration timing: **registered_while_recruiting**
Last update: **2020-04-08, 1399/01/20**
Update count: **0**

Registration date
2020-04-08, 1399/01/20

Registrant information

Name
Azadeh Eshraghi

Name of organization / entity
Department of Clinical Pharmacy, Faculty of Pharmacy-International Campus, Iran University of Medica

Country
Iran (Islamic Republic of)

Phone
+98 86709

Email address
eshraghi.a@iums.ac.ir

Recruitment status
Recruitment complete

Funding source

Expected recruitment start date
2020-03-30, 1399/01/11

Expected recruitment end date
2020-06-21, 1399/04/01

Actual recruitment start date
empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
Study of the Efficacy of Teicoplanin on mortality rate of patients with COVID-19 Infection: A randomized clinical trial

Public title
Evaluation the Effect of Ticoplanin in Patients With Coronavirus Disease

Purpose
Health service research
Inclusion/Exclusion criteria
Inclusion criteria:
Laboratory confirmed COVID-19 with RT-PCR Laboratory confirmed COVID-19 with lung CT scan
Exclusion criteria:
Chronic kidney Disease Acute kidney injury Pregnancy Breastfeeding
Age
No age limit
Gender
Both

Phase
3
Groups that have been masked
No information
Sample size
Target sample size: **40**
Randomization (investigator's opinion)
Randomized
Randomization description
randomization to intervention and control groups. Simple randomization will be generated with a computer
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Other
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Iran University of Medical Sciences
Street address
Hazrate Rasoole Akram Hospital,Niayesh St,Satarkhan Av
City
Tehran
Province
Tehran
Postal code
1449614535
Approval date
2020-03-30, 1399/01/11
Ethics committee reference number
IR.IUMS.REC.1399.058

Health conditions studied

1

Description of health condition studied
COVID-19
ICD-10 code
U07.1
ICD-10 code description
Coronavirus infection, unspecified

Primary outcomes

1

Description
Measurement of inflammatory markers (CRP)
Timepoint
at baseline and discharge time
Method of measurement
ELISA

2

Description
WBC count
Timepoint
at baseline and discharge time
Method of measurement
Blood count

3

Description
Evaluation of lung CT scan
Timepoint
at baseline and discharge time
Method of measurement
Radiologic finding

4

Description
Evaluation of inflammatory marker ESR
Timepoint
at baseline and discharge time
Method of measurement
Blood count

Secondary outcomes

1

Description
Body temperature
Timepoint
at baseline and discharge time
Method of measurement
Thermometer

2

Description
Fever
Timepoint

at baseline and discharge time

Method of measurement

Thermometer

3

Description

Respiratory rate >24/min

Timepoint

at baseline and discharge time

Method of measurement

Counting of respiratory rate in minutes

4

Description

Systolic blood pressure <90 mm Hg

Timepoint

at baseline and discharge time

Method of measurement

Manometer

5

Description

Oxygen saturation

Timepoint

at baseline and discharge time

Method of measurement

oximeter Pulse

6

Description

Pulse rate

Timepoint

at baseline and discharge time

Method of measurement

Counting of pulse rate in minutes

7

Description

Level of consciousness or new confusion

Timepoint

at baseline and discharge time

Method of measurement

With glasgow coma scale

Intervention groups

1

Description

Intervention group: Tab Hydroxychloroquine 200 mg two tablet P.O. BID for first day then 200 mg BID seven days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for seven days or Tab atazabavir-ritonavir 100/300 mg P.O one tablet daily for seven days plus Teicoplanin IV 400 mg daily for 1 weeks.

Category

Treatment - Drugs

2

Description

Control group: Tab Hydroxychloroquine 200 mg two tablet P.O. BID for first day then 200 mg BID seven days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for seven days or Tab atazabavir-ritonavir 100/300 mg P.O one tablet daily for seven days

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Hazrate Rasoole Akram Hospital

Full name of responsible person

Azadeh Eshraghi، Saeed Kalantari

Street address

Hazrate Rasoole Akram Hospital,Niayesh St,Satarkhan Av, Tehran

City

Tehran

Province

Tehran

Postal code

۱۴۴۵۶۱۳۱۳۱

Phone

+98 21 6435 2564

Email

aepharm@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Iran University of Medical Sciences

Full name of responsible person

Dr.Motevalian

Street address

Iran University of Medical Sciences, Shahid Hemmat Highway, Tehran

City

Tehran

Province

Tehran

Postal code

1449614535

Phone

+98 21 8670 2503

Email

research-m@iums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

No

Title of funding source

Iran University of Medical Sciences

Proportion provided by this source
100

Public or private sector
Public

Domestic or foreign origin
Domestic

Category of foreign source of funding
empty

Country of origin

Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact

Name of organization / entity
Iran University of Medical Sciences

Full name of responsible person
Azadeh Eshraghi

Position
Assistant Professor

Latest degree
Ph.D.

Other areas of specialty/work
Medical Pharmacy

Street address
Hazrate Rasoole Akram Hospital,Niayesh St,Satarkhan Av, Tehran

City
Tehran

Province
Tehran

Postal code
1449614535

Phone
+98 21 6435 2564

Email
aepharm@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Iran University of Medical Sciences

Full name of responsible person
Azadeh Eshraghi

Position
Assistant Professor

Latest degree
Ph.D.

Other areas of specialty/work
Medical Pharmacy

Street address
Hazrate Rasoole Akram Hospital,Niayesh St,Satarkhan Av, Tehran

City
Tehran

Province
Tehran

Postal code
1449614535

Phone
+98 21 6435 2564

Email
aepharm@gmail.com

Person responsible for updating data

Contact

Name of organization / entity
Iran University of Medical Sciences

Full name of responsible person
Saeed Kalantari

Position
Assistant professor

Latest degree
Specialist

Other areas of specialty/work
Infectious diseases

Street address
Hazrate Rasoole Akram Hospital,Niayesh St,Satarkhan Av, Tehran,

City
Tehran

Province
Tehran

Postal code
1449614535

Phone
+98 21 6435 2564

Email
kalantari.s@iums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available

Study Protocol
Yes - There is a plan to make this available

Statistical Analysis Plan
Yes - There is a plan to make this available

Informed Consent Form
No - There is not a plan to make this available

Clinical Study Report
Yes - There is a plan to make this available

Analytic Code
Yes - There is a plan to make this available

Data Dictionary
No - There is not a plan to make this available

Title and more details about the data/document
Main outcome

When the data will become available and for how long
Start of access period 6 months after printing results

To whom data/document is available
Researchers working in academic institutions

Under which criteria data/document could be used
Total of data

From where data/document is obtainable
Email address of aepharm@gmail.com

What processes are involved for a request to access data/document

By email

Comments